Calcilytics are
pharmaceutical drugs that act as
antagonists at the
calcium-sensing receptor (CaSR). This increases the secretion of
parathyroid hormone (PTH), which has a temporary
anabolic effect on
bone tissue, producing an increase in both bone volume and
bone density due to increased bone deposition and resorption. However, long term use of these causes resorption, degrading the bone to raise blood calcium.[1] Consequently, these drugs have been researched for the treatment of
osteoporosis,[2][3][4] though with only limited success.[5] More recent research has suggested a number of additional applications for these drugs, such as hyperresponsiveness and
inflammation in allergic
asthma.[6][7][8][9]
^Nemeth EF, Shoback D (June 2013). "Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders". Best Practice & Research. Clinical Endocrinology & Metabolism. 27 (3): 373–84.
doi:
10.1016/j.beem.2013.02.008.
PMID23856266.
Calcilytics are
pharmaceutical drugs that act as
antagonists at the
calcium-sensing receptor (CaSR). This increases the secretion of
parathyroid hormone (PTH), which has a temporary
anabolic effect on
bone tissue, producing an increase in both bone volume and
bone density due to increased bone deposition and resorption. However, long term use of these causes resorption, degrading the bone to raise blood calcium.[1] Consequently, these drugs have been researched for the treatment of
osteoporosis,[2][3][4] though with only limited success.[5] More recent research has suggested a number of additional applications for these drugs, such as hyperresponsiveness and
inflammation in allergic
asthma.[6][7][8][9]
^Nemeth EF, Shoback D (June 2013). "Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders". Best Practice & Research. Clinical Endocrinology & Metabolism. 27 (3): 373–84.
doi:
10.1016/j.beem.2013.02.008.
PMID23856266.